natgillin/translations-raw huggingface dataset:
• weight decrease, weight increase; 
• gubitak tjelesne težine, povećanje tjelesne težine;
Empty the contents of the syringe in a glass of water by pushing down the plunger. 
Ispraznite sadržaj štrcaljke u čašu vode potiskivanjem klipa do dna štrcaljke.
The extent of absorption is dose-independent and is not altered by food. 
Opseg apsorpcije ne ovisi o dozi, niti se mijenja u prisutnosti hrane.
Production of the primary metabolite, ucb L057, is not supported by liver cytochrome P450 isoforms. 
Nastajanje primarnog metabolita, ucb L057, nije ovisno o izoformama jetrenog citokroma P450.
A retrospective assessment of pharmacokinetic interactions in children and adolescents with epilepsy (4 to 17 years) confirmed that adjunctive therapy with orally administered levetiracetam did not influence the steady-state serum concentrations of concomitantly administered carbamazepine and valproate. 
Na temelju retrospektivne ocjene farmakokinetičkih interakcija u djece i adolescenata s epilepsijom (4 do 17 godina) potvrđeno je da dodatno oralno liječenje levetiracetamom ne utječe na ravnotežne serumske koncentracije istodobno primijenjenog karbamazepina i valproata.
Levetiracetam is used for the epilepsy form in which the fits initially affect only one side of the brain, but could thereafter extend to larger areas on both sides of the brain (partial onset seizure with or without secondary generalisation). 
Epilepsija je stanje u kojem bolesnici imaju ponavljane epileptičke napadaje, Levetiracetam se koristi za oblik epilepsije u kojem napadaji započinju u jednoj strani mozga, ali se nakon toga mogu proširiti na veće područje u obje strane mozga (parcijalni napadaj sa ili bez sekundarne generalizacije).
• a more severe form of rash causing skin peeling in more than 30% of the body surface (toxic epidermal necrolysis); 
• puno teži oblik osipa koji uzrokuje ljuštenje kože u više od 30 % površine tijela (toksična epidermalna nekroliza)
• rhabdomyolysis (breakdown of muscle tissue) and associated blood creatine phosphokinase increase. 
• rabdomioliza (oštećenje mišićnog tkiva) i povezano povećanje kreatin fosfokinaze u krvi.
Six-month seizure freedom was achieved in 73.0% of levetiracetam-treated patients and 72.8% of carbamazepine-CR treated patients; the adjusted absolute difference between treatments was 0.2% (95 % CI: -7.8 8.2). 
73,0 % bolesnika liječenih levetiracetamom i 72,8 % bolesnika liječenih karbamazepinom s kontroliranim otpuštanjem (CR) bilo je šest mjeseci bez napadaja: prilagođena apsolutna razlika između liječenja bila je 0,2 % (95% CI: -7,8 8,2).
In addition, 101 infants aged less than 12 months have been exposed in a post authorization safety study. 
Dodatno, 101 dojenče mlađe od 12 mjeseci bilo je izloženo lijeku u ispitivanju sigurnosti primjene lijeka nakon stavljanja lijeka u promet.
Therefore there is no need for plasma level monitoring of levetiracetam. 
Stoga nije potrebno praćenje razine levetiracetama u plazmi.
Dose in adults and adolescents (12 to 17 years): 
Doza u odraslih i adolescenata (12 do 17 godina):
Thrombocytopenia, leukopenia 
Trombocitopenija, leukopenija
The dose can be further increased by 250 mg twice daily every two weeks depending upon the clinical response. 
Doza se može dalje povećavati za po 250 mg dva puta na dan svaka dva tjedna, ovisno o kliničkom odgovoru.
Do not use this medicine after the expiry date which is stated on the cardboard box and bottle after EXP:. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i boci iza oznake „EXP“.
• weakness, feel light-headed or dizzy or have difficulty breathing, as these may be signs of a serious allergic (anaphylactic) reaction; 
• slabost, osjećaj ošamućenosti ili vrtoglavice ili poteškoće s disanjem, budući da to mogu biti znakovi ozbiljne alergične (anafilaktičke) reakcije
In the population pharmacokinetic analysis conducted in patients from 1 month to 16 years of age, body weight was significantly correlated to apparent clearance (clearance increased with an increase in body weight) and apparent volume of distribution. 
Farmakokinetička analiza populacije obavljena u bolesnika u dobi od 1. mjeseca do 16. godine života pokazala je značajnu korelaciju tjelesne težine s prividnim klirensom (klirens se povećavao s porastom tjelesne težine) i s prividnim volumenom distribucije.
(2) Following dialysis, a 250 to 500 mg supplemental dose is recommended. 
(2) Nakon dijalize preporučuje se dopunska doza od 250 ili 500 mg.
Injury 
Ozljeda
Peak plasma concentrations (Cmax) are achieved at 1.3 hours after dosing. 
Vršna koncentracija u plazmi (Cmax) postiže se 1,3 sata nakon uzimanja lijeka.
Adverse reactions are presented in the order of decreasing seriousness and their frequency is defined as follows: very common (≥ 1/10); common (≥ 1/100 to <1/10); uncommon (≥ 1/1,000 to 
Nuspojave su prikazane u padajućem nizu s obzirom na ozbiljnost i njihova učestalost je definirana na sljedeći način: vrlo često (≥1/10), često (≥1/100 i <1/10), manje često (≥1/1000 i <1/100), rijetko (≥1/10 000 i <1/1000) i vrlo rijetko (<1/10 000).
The CLcr in ml/min may be estimated from serum creatinine (mg/dl) determination, for adults and adolescents weighing 50 kg or more, the following formula: 
Klirens kreatinina u ml/min može se procijeniti iz serumskog kreatinina (mg/dl), za odrasle i adolescente teške 50 kg ili više, pomoću sljedeće formule:
For adult patients, refer to the following table and adjust the dose as indicated. 
Za odrasle bolesnike prilagodite dozu prema sljedećoj tablici.
Pre-marketing data from clinical studies conducted in adults indicate that levetiracetam did not influence the serum concentrations of existing antiepileptic medicinal products (phenytoin, carbamazepine, valproic acid, phenobarbital, lamotrigine, gabapentin and primidone) and that these antiepileptic medicinal products did not influence the pharmacokinetics of levetiracetam. 
Rezultati kliničkih ispitivanja na odraslim bolesnicima prije stavljanja lijeka u promet pokazuju da levetiracetam ne utječe na serumske koncentracije postojećih antiepileptika (fenitoin, karbamazepin, valproična kiselina, fenobarbital, lamotrigin, gabapentin i primidon) te da ti antiepileptici ne utječu na farmakokinetiku levetiracetama.
Propylene glycol (E1520) 
Propilenglikol (E1520)
• If you notice any slow down in the growth or unexpected puberty development of your child, 
• Ako primijetite usporen rast ili neočekivan razvoj djeteta u pubertetu, obavijestite svog liječnika.
A double-blind, placebo-controlled paediatric safety study with a non-inferiority design has assessed the cognitive and neuropsychological effects of levetiracetam in children 4 to 16 years of age with partial onset seizures. 
Dvostruko slijepo i placebom kontrolirano pedijatrijsko ispitivanje o sigurnosti s neinferiornim dizajnom ocijenilo je kognitivne i neuropsihološke učinke levetiracetama u djece od 4. do 16. godine života s parcijalnim napadajima.
• sudden decrease in kidney function; 
• iznenadno smanjenje bubrežne funkcije;
The physician should prescribe the most appropriate pharmaceutical form, presentation and strength according to age, weight and dose. 
Liječnik treba propisati najprikladniji farmaceutski oblik, vrstu pakiranja i jačinu lijeka u skladu s dobi, tjelesnom težinom i dozom.
For children with renal impairment, levetiracetam dose needs to be adjusted based on the renal function as levetiracetam clearance is related to renal function. 
Kod djece s oštećenjem bubrega treba prilagoditi dozu levetiracetama s obzirom na bubrežnu funkciju jer je klirens levetiracetama povezan s bubrežnom funkcijom.
Concomitant administration of levetiracetam and methotrexate has been reported to decrease methotrexate clearance, resulting in increased/prolonged blood methotrexate concentration to potentially toxic levels. 
Pri istodobnoj primjeni levetiracetama i metotreksata prijavljeno je smanjenje klirensa metotreksata što uzrokuje povišenu/zadržanu koncentraciju metotreksata u krvi do potencijalno toksičnih razina.
The dose level of 1,800 mg/kg/day induced a marked maternal toxicity and a decrease in foetal weight associated with increased incidence of fetuses with cardiovascular/skeletal anomalies. 
Doza od 1800 mg/kg/dan izazvala je znatnu maternalnu toksičnost i smanjenje fetalne težine, povezane s povećanom pojavnošću fetusa s anomalijama srčano-žilnog sustava i kostura.
Push the plunger in slowly to the graduation mark corresponding to the quantity in milliliters (ml) prescribed by your doctor (Figure 7). 
Polako potisnite klip do oznake koja odgovara količini u mililitrima (ml) koju je propisao Vaš liječnik
The apparent body clearance was 1.1 ml/min/kg. 
Prividni tjelesni klirens bio je 1,1 ml/min/kg.
Pull the plunger down and fill the syringe with a quantity of solution slightly beyond the prescribed dose (Figure 5). 
Izvucite klip i napunite štrcaljku s količinom otopine koja je malo veća od propisane doze (slika 5).
The in vitro data and in vivo interaction data on oral contraceptives, digoxin and warfarin indicate that no significant enzyme induction is expected in vivo. 
In vitro i in vivo podaci o interakciji s oralnim kontraceptivima, digoksinom i varfarinom upućuju na to da nije očekivana značajna indukcija enzima in vivo.
• delirium; 
• delirij;
The active substance, levetiracetam, is a pyrrolidone derivative (S-enantiomer of α-ethyl-2-oxo-1pyrrolidine acetamide), chemically unrelated to existing antiepileptic active substances. 
Djelatna tvar, levetiracetam, jest derivat pirolidona (S-enantiomer α-etil-2-okso-1-pirolidinacetamida), kemijski različit od postojećih antiepileptičnih djelatnih tvari.
In most subjects with severe hepatic impairment, the clearance of levetiracetam was reduced by more than 50% due to a concomitant renal impairment (see section 4.2). 
U većine osoba s teškim oštećenjem jetre klirens levetiracetama smanjen je za više od 50 % uslijed popratnog oštećenja bubrega (vidjeti dio 4.2).
The adverse reaction profile presented below is based on the analysis of pooled placebo-controlled clinical trials with all indications studied, with a total of 3,416 patients treated with levetiracetam. 
Profil nuspojava opisan niže temelji se na analizi zbirnih placebom konroliranih kliničkih istraživanja za sve ispitivane indikacije, u kojima je levetiracetamom liječeno ukupno 3416 bolesnika.
If levetiracetam has to be discontinued it is recommended to withdraw it gradually (e.g. in adults and adolescents weighing more than 50 kg: 500 mg decreases twice daily every two to four weeks; in infants older than 6 months, children and adolescents weighting less than 50 kg: dose decrease should not exceed 10 mg/kg twice daily every two weeks; in infants (less than 6 months): dose decrease should not exceed 7 mg/ kg twice daily every two weeks). 
Ako treba prekinuti liječenje levetiracetamom, preporučuje se postupni prekid (npr. u odraslih i adolescenata tjelesne težine veće od 50 kg: smanjenje za 500 mg dva puta na dan svaka dva do četiri tjedna; u dojenčadi starije od 6 mjeseci, djece i adolescenata tjelesne težine manje od 50 kg: smanjenje doze ne smije biti veće od 10 mg/kg dva puta na dan svaka dva tjedna; u dojenčadi (mlađe od 6
In patients with severely impaired hepatic function, assessment of renal function is recommended before dose selection (see section 4.2). 
. U bolesnika s teško oštećenom jetrenom funkcijom treba odrediti funkciju bubrega prije odabira doze (vidjeti dio 4.2).
Adverse effects not observed in clinical studies but seen in the rat and to a lesser extent in the mouse at exposure levels similar to human exposure levels and with possible relevance for clinical use were liver changes, indicating an adaptive response such as increased weight and centrilobular hypertrophy, fatty infiltration and increased liver enzymes in plasma. 
Nuspojave značajne za kliničku primjenu koje nisu primijećene tijekom kliničkih studija, a koje su nađene kod štakora i u manjoj mjeri kod miševa izloženih razinama sličnim razinama izloženosti kod ljudi, bile su promjene jetre koje su upućivale na prilagodbeni odgovor kao na primjer povećana težina i centrilobularna hipertrofija, masna infiltracija jetre i povišene razine jetrenih enzima u plazmi.
At 3,600 mg/kg/day, in only one of the 2 EFD studies, there was a slight decrease in foetal weight associated with a marginal increase in skeletal variations/minor anomalies. 
Pri dozi od 3600 mg/kg/dan samo je u jednom od dva EFD ispitivanja uočeno blago smanjenje fetalne težine povezano s marginalnim porastom varijacija kostura/malih anomalija.
The renal clearance of levetiracetam and ucb L057 is 0.6 and 4.2 ml/min/kg respectively indicating that levetiracetam is excreted by glomerular filtration with subsequent tubular reabsorption and that the primary metabolite is also excreted by active tubular secretion in addition to glomerular filtration. 
Bubrežni klirens levetiracetama i ucb L057 jest 0,6, odnosno 4,2 ml/min/kg, što ukazuje da se levetiracetam izlučuje glomerularnom filtracijom nakon čega dolazi do tubularne reapsorpcije te da se glavni metabolit osim glomerularnom filtracijom izlučuje i aktivnom tubularnom sekrecijom.
This recommendation is based on a study in adult renally impaired patients. 
Ta preporuka zasnovana je na ispitivanju u odraslih bolesnika s oštećenjem bubrega.
In vitro and in vivo experiments suggest that levetiracetam does not alter basic cell characteristics and normal neurotransmission. 
Eksperimenti in vitro i in vivo pokazuju da levetiracetam ne utječe na osnovna svojstva stanica i normalnu neurotransmisiju.
If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. 
Ako Vam je liječnik rekao da imate bolest nepodnošenja nekih šećera, prije nego što počnete uzimati ovaj lijek posavjetujte se sa svojim liječnikom.
Your doctor will prescribe the most appropriate pharmaceutical form of levetiracetam according to the age, weight and dose. 
Liječnik će propisati najprikladniji farmaceutski oblik levetiracetama sukladno dobi, tjelesnoj težini i dozi.
Contents of the pack and other information What Levetiracetam Actavis Group contains 
Sadržaj pakiranja i druge informacije Što Levetiracetam Actavis Group sadrži
Contains E216, E218, maltitol liquid (E965) and propylene glycol (E1520). 
Sadrži E216, E218, tekući maltitol (E965) i propilenglikol (E1520).
It was concluded that levetiracetam was not different (non inferior) from placebo with regard to the change from baseline of the Leiter-R Attention and Memory, Memory Screen Composite score in the per-protocol population. 
Zaključeno je da se levetiracetam u populaciji po protokolu nije razlikovao od placeba (nije bio inferioran) s obzirom na promjene od početnih vrijednosti rezultata testiranja dobivenih ljestvicom Leiter-R Attention and Memory, Memory Screen Composite.
Group 
Skupina
In children and adolescents aged 4 to 16 years, vomiting (very common, 11.2%), agitation (common, 3.4%), mood swings (common, 2.1%), affect lability (common, 1.7%), aggression (common, 8.2%), abnormal behaviour (common, 5.6%), and lethargy (common, 3.9%) were reported more frequently than in other age ranges or in the overall safety profile. 
U djece i adolescenata u dobi 4 do 16 godina povraćanje (vrlo često, 11,2%), agitacija (često, 3,4%), promjene raspoloženja (često, 2,1%), labilnost afekta (često, 1,7%), agresija (često, 8,2%), poremećaj ponašanja (često, 5,6%) i letargija (često, 3,9%) bili su prijavljeni češće nego u drugim dobnim rasponima ili u cjelokupnom sigurnosnom profilu.
Dose recommendations for infants from 6 months of age, children and adolescents: 
Preporučene doze za dojenčad od 6. mjeseca života, djecu i adolescente:
The recommended starting dose is 250 mg twice daily which should be increased to an initial therapeutic dose of 500 mg twice daily after two weeks. 
Preporučena početna doza je 250 mg dva puta na dan koju nakon dva tjedna treba povećati do inicijalne terapijske doze od 500 mg dva puta na dan.
However subjects, who took levetiracetam in the long-term open label follow-up study, did not experience a worsening, on average, in their behavioural and emotional functioning; in particular measures of aggressive behavior were not worse than baseline. 
No u ispitanika koji su uzimali levetiracetam tijekom dugoročnog, otvorenog ispitivanja provedenog praćenjem u prosjeku nije bilo pogoršanja bihevioralnog i emocionalnog funkcioniranja, a osobito nije bilo pogoršanja pokazatelja agresivnog ponašanja u odnosu na početno stanje.
The contents of the syringe can also be given directly from the syringe into the mouth or emptied onto a spoon (Figure 3). 
Sadržaj štrcaljke možete izravno dati u usta ili ga isprazniti na žlicu (slika 3).
The use of levetiracetam has been very rarely associated with acute kidney injury, with a time to onset ranging from a few days to several months. 
Primjena levetiracetama vrlo je rijetko bila povezana s akutnim oštećenjem bubrega, a može se pojaviti u rasponu od nekoliko dana do nekoliko mjeseci od početka primjene.
In addition, levetiracetam does not affect the in vitro glucuronidation of valproic acid. 
Levetiracetam ne utječe na glukuronidaciju valproične kiseline in vitro.
For children aged 6 months to less than 4 years 
Za djecu u dobi od 6 mjeseci do manje od 4 godine
233 of these patients were treated with levetiracetam in placebo-controlled studies. 
233 od tih bolesnika bilo je liječeno levetiracetamom u placebom kontroliranim ispitivanjima.
The total daily dose was administered twice daily. 
Ukupna se dnevna doza davala dva puta na dan.
• decreased blood sodium concentration; 
• snižena koncentracija natrija u krvi;
58.3% of the levetiracetam treated patients and 23.3% of the patients on placebo had at least a 50% reduction in myoclonic seizure days per week. 
58,3 % bolesnika liječenih levetiracetamom i 23,3 % bolesnika koji su dobivali placebo imalo je barem 50 %-tno smanjenje broja dana s miokloničkim napadajima tjedno.
Push the tip of the syringe into the adaptor opening. 
Utisnite vrh štrcaljke u otvor nastavka.
At the beginning of the treatment or at dose increase side effects like sleepiness, tiredness and dizziness may be more common. 
Na početku liječenja ili nakon povećanja doze nuspojave poput pospanosti, umora i omaglice, mogu se javiti češće.
What Levetiracetam Actavis Group is and what it is used for 
Što je Levetiracetam Actavis Group i za što se koristi
In a study reflecting clinical practice, the concomitant antiepileptic medication could be withdrawn in a limited number of patients who responded to levetiracetam adjunctive therapy (36 adult patients out of 69). 
U ispitivanju koje je bilo odraz kliničke prakse bilo je moguće prekinuti istodobno antiepileptičko liječenje u ograničenog broja bolesnika koji su odgovorili na dodatno liječenje levetiracetamom (36 od
Monotherapy for adults and adolescents from 16 years of age 
Doziranje Monoterapija za odrasle i adolescente od 16. godine života
Add-on therapy for adults (≥18 years) and adolescents (12 to 17 years) weighing 50 kg or more 
Dodatna terapija za odrasle (≥18 godina) i adolescente (12 do 17 godina) teške 50 kg ili više
No enantiomeric interconversion was evidenced in vivo for either levetiracetam or its primary metabolite. 
Interkonverzije enantiomera nisu utvrđene in vivo ni za levetiracetam ni za njegov glavni metabolit.
In a pooled analysis, the percentage of patients who achieved 50% or greater reduction from baseline in the partial onset seizure frequency per week at stable dose (12/14 weeks) was of 27.7%, 31.6% and 41.3% for patients on 1,000, 2,000 or 3,000 mg levetiracetam respectively and of 12.6% for patients on placebo. 
Analizom zbirnih podataka utvrđeno je da je postotak bolesnika kod kojih je postignuto 50 %-tno ili više smanjenje od početne učestalosti djelomičnih napadaja tjedno uz konstantnu dozu (12/14 tjedana) bio 27,7 % kod uzetih 1000 mg, 31,6 % kod uzetih 2000 mg i 41,3 % kod uzetih 3000 mg levetiracetama te 12,6 % kod uzimanja placeba.
The pharmacokinetic profile is comparable in healthy volunteers and in patients with epilepsy. 
Farmakokinetički profil zdravih dobrovoljaca i bolesnika s epilepsijom jest komparabilan.
Dose in infants (1 month to less than 6 months): 
Doza u dojenčadi (1 mjesec do manje od 6 mjeseci):
The apparent body clearance of both levetiracetam and of its primary metabolite is correlated to the creatinine clearance. 
Prividni tjelesni klirens levetiracetama i njegovog glavnog metabolita povezan je s klirensom kreatinina.
In anuric end-stage renal disease adult subjects the half-life was approximately 25 and 3.1 hours during interdialytic and intradialytic periods, respectively. 
U odraslih bolesnika s anuričnom krajnjom fazom bubrežne bolesti poluvijek iznosi približno 25 i 3,1 sati u razdoblju između dijalize, odnosno tijekom dijalize.
No new safety concerns for levetiracetam were identified for infants less than 12 months of age with epilepsy. 
Nisu utvrđeni novi problemi u vezi sa sigurnošću primjene levetiracetama u dojenčadi mlađe od 12 mjeseci s epilepsijom.
This medicine contains less than 1 mmol sodium (23 mg) per ml, that is to say essentially ‘sodiumfree'. 
Ovaj lijek sadrži manje od 1 mmol (23 mg) natrija po ml, tj. zanemarive količine natrija.
If any bubbles appear in the syringe keep the bottle upside down and slightly push in the plunger and pull it back again. 
Ako se u štrcaljki pojave mjehurići, neka boca bude i dalje okrenuta naopako.
In vitro, levetiracetam and its primary metabolite have been shown not to inhibit the major human liver cytochrome P450 isoforms (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 and 1A2), glucuronyl transferase (UGT1A1 and UGT1A6) and epoxide hydroxylase activities. 
In vitro je pokazano da levetiracetam i njegov glavni metabolit ne inhibiraju aktivnost izoformi glavnog humanog citokroma P450 (CYP3A4, 2A6, 2C9, 2C19, 2D6, 2E1 i 1A2), glukuronil transferaze
The mechanism of action of levetiracetam still remains to be fully elucidated. 
Mehanizam djelovanja levetiracetama nije u potpunosti razriješen.
Peak plasma concentration was observed 0.5 to 1.0 hour after dosing. 
Vršna koncentracija u plazmi postignuta je 0,5 do 1,0 sat nakon uzimanja lijeka.
In patients aged 1 month to less than 4 years, a total of 190 patients have been treated with levetiracetam in placebo-controlled and open label extension studies. 
U bolesnika u dobi od 1 mjeseca do manje od 4 godine, ukupno 190 bolesnika liječeno je levetiracetamom u placebom kontroliranim i ispitivanjima otvorenog produžetka.
• diplopia (double vision), vision blurred; 
• diplopija (dvoslike), zamagljen vid;
Levetiracetam Actavis Group is indicated as adjunctive therapy 
Levetiracetam Actavis Group je indiciran kao dodatna terapija
Furthermore, levetiracetam has been shown in in vitro studies to bind to a specific site in rodent brain tissue. 
Nadalje, ispitivanjima in vitro pokazano je da se levetiracetam veže za specifično mjesto u moždanom tkivu glodavaca.
• flu-like symptoms and a rash on the face followed by an extended rash with a high temperature, increased levels of liver enzymes seen in blood tests and an increase in a type of white blood cell (eosinophilia) and enlarged lymph nodes (Drug Reaction with Eosinophilia and Systemic Symptoms [DRESS]); 
• simptome nalik gripi i osip na licu popraćen proširenim osipom s visokom tjelesnom temperaturom, povećane vrijednosti jetrenih enzima u krvnim testovima, povećanje posebne vrste bijelih krvnih stanica (eozinofilija) i povećane limfne čvorove (reakcija na lijek s eozinofilijom i sistemskim simptomima [DRESS])
Levetiracetam elimination is correlated to creatinine clearance. 
Eliminacija levetiracetama povezana je s klirensom kreatinina.
1,500 mg twice daily (1) Children 25 kg or less should preferably start the treatment with Levetiracetam Actavis Group 
1500 mg dva puta na dan (1) U djece od 25 kg ili manje liječenje je najbolje započeti Levetiracetam Actavis Group 100 mg/ml oralnom otopinom.
• liver failure, hepatitis; 
• zatajenje jetre, hepatitis;